Summary:
We retrospectively analysed the outcome of voluntary unrelated donor (VUD)-SCT in 56 patients after conditioning without or with ATG. All received partially lymphocyte-depleted grafts. Four of 17 patients (24%) who were not given ATG rejected their grafts, as did one of 33 (3%) conditioned with ATG (P=0.02). The incidences of acute graft-versus-host disease grade III/IV were 29 and 6%, respectively (P=0.02), and probabilities of 1-year transplant-related mortality were 64% (95% CI, 44–84%) and 27% (95% CI, 12–42%), respectively (P=0.004). Projected at 3 years, probability of survival was 18% (95% CI, 2–34%) after conditioning without ATG and 60% (95% CI, 43–70%) after conditioning with ATG (P=0.002). Probabilities of disease-free survival (DFS) were 18% (95% CI, 2–34%) and 45% (95% CI, 27–63%), respectively (P=0.005). Patients who did not receive ATG had a probability of current DFS of 18% (95% CI, 3–34%) and this was 60% (95% CI, 43–77%) for the patients conditioned with ATG (P<0.001). We conclude that the addition of ATG to the conditioning regimen is associated with a significantly more favourable outcome in recipients of partially T-cell-depleted grafts from VUDs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
O'Reilly RJ . Allogeneic bone marrow transplantation: current status and future directions. Blood 1983; 62: 941–964.
Bortin MM, Horowitz MM, Rimm AA . Increasing utilization of allogeneic bone marrow transplantation. Results of the 1988–1990 survey. Ann Intern Med 1992; 116: 505–512.
Bacigalupo A, Oneto R, Bruno B et al. Current results of bone marrow transplantation in patients with acquired severe aplastic anemia. Report of the European Group for Blood and Marrow transplantation. On behalf of the Working Party on Severe Aplastic Anemia of the European Group for Blood and Marrow Transplantation. Acta Haematol 2000; 103: 19–25.
Hansen JA, Yamamoto K, Petersdorf E, Sasazuki T . The role of HLA matching in hematopoietic cell transplantation. Rev Immunogenet 1999; 1: 359–373.
Marmont AM, Horowitz MM, Gale RP et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120–2130.
Davison GM, Novitzky N, Kline A et al. Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells. Transplantation 2000; 69: 1341–1347.
Preijers FW, van Hennik PB, Schattenberg A et al. Counterflow centrifugation allows addition of appropriate numbers of T cells to allogeneic marrow and blood stem cell grafts to prevent severe GVHD without substantial loss of mature and immature progenitor cells. Bone Marrow Transplant 1999; 23: 1061–1070.
Van der Meer A, Joosten I, Ruiter J, Allebes WA . A single [3H]thymidine-based limiting dilution analysis to determine HTLp and CTLp frequencies for bone marrow donor selection. Bone Marrow Transplant 1997; 20: 149–155.
Van der Meer A, Joosten I, Schattenberg A et al. Cytotoxic T-lymphocyte precursor frequency (CTLp-f) as a tool for distinguishing permissible from non-permissible class I mismatches in T-cell-depleted allogeneic bone marrow transplantation. Br J Haematol 2000; 111: 685–694.
Glucksberg H, Storb R, Fefer A et al. CIinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295–304.
Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. Am J Med 1980; 69: 204–217.
Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041–2050.
Schaap N, Schattenberg A, Bar B et al. Outcome of transplantation for standard-risk leukaemia with grafts depleted of lymphocytes after conditioning with an intensified regimen. Br J Haematol 1997; 98: 750–759.
Soiffer RJ, Mauch P, Tarbell NJ et al. Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow. Bone Marrow Transplant 1991; 7: 23–33.
McGlave PB, Shu XO, Wen W et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 2000; 95: 2219–2225.
Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593–602.
Bacigalupo A, Lamparelli T, Gualandi F et al. Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants. Biol Blood Marrow Transplant 2002; 8: 656–661.
Remberger M, Storer B, Ringden O, Anasetti C . Between pretransplant thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 2002; 29: 391–397.
Curtis RE, Travis LB, Rowlings PA et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94: 2208–2216.
Van Esser JWJ, Niesters HGM, Van der Holt B et al. Prevention of Ebstein–Barr virus-lymphoproliferative disease by molecular monitoring and pre-emptive rituximab in high-risk patients after allogeneic hematopoietic stem cell transplantation. Blood 2002; 99: 4364–4369.
Acknowledgements
We thank all voluntary unrelated donors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schattenberg, A., Meer, A., Preijers, F. et al. Addition of ATG to the conditioning regimen is a major determinant for outcome after transplantation with partially lymphocyte-depleted grafts from voluntary unrelated donors. Bone Marrow Transplant 33, 1115–1121 (2004). https://doi.org/10.1038/sj.bmt.1704490
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704490
Keywords
This article is cited by
-
Anti-thymocyte globulin’s activity against acute myeloid leukemia stem cells
Bone Marrow Transplantation (2019)
-
Effect of antithymocyte globulin on HLA-mismatched unrelated transplantation
International Journal of Hematology (2019)
-
Impact of low-dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation
International Journal of Hematology (2016)
-
IL15 levels on day 7 after hematopoietic cell transplantation predict chronic GVHD
Bone Marrow Transplantation (2013)
-
Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab
Bone Marrow Transplantation (2013)